Literature DB >> 872497

Digoxin kinetics in patients with thyroid dysfunction.

J R Lawrence, D J Sumner, W J Kalk, W A Ratcliffe, B Whiting, K Gray, M Lindsay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 872497     DOI： 10.1002/cpt19772217

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  8 in total

Review 1.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 2.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 3.  Disease-related alterations in cardiac glycoside disposition.

Authors:  H R Ochs; D J Greenblatt; G Bodem; H J Dengler
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of digoxin 1980.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

5.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

6.  Anaesthetic problems associated with the treatment of cardiovascular disease: I. Digitalis toxicity.

Authors:  D C Chung
Journal:  Can Anaesth Soc J       Date:  1981-01

Review 7.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

8.  Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells.

Authors:  Naoki Nishio; Toshiya Katsura; Ken-ichi Inui
Journal:  Pharm Res       Date:  2007-11-15       Impact factor: 4.200
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.